CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.
Company Profile
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Company Contact
CytoDyn Inc.
1111 Main Street
Suite 660
Vancouver, WA 98660
T: 360-980-8524
F: 360-799-5954
info@cytodyn.com